Gold prices steady ahead of Fed decision; weekly weakness noted
Investing.com -- Uniphar PLC on Tuesday delivered approximately 8% organic gross profit growth in the first half of 2025 and double-digit adjusted EPS growth, while reiterating its full-year gross profit and mid-term EBITDA guidance.
The company reported strong performance across all divisions, with Pharma growing at double-digits, Medtech at high-single-digits, and Supply Chain & Retail at low-single-digits, all in line with full-year guidance.
Net bank debt stood at 1.9x EBITDA at the end of June, which includes the impact of a €35 million share buyback program completed during the period.
Uniphar cited "strong trading momentum" heading into the second half of the year, with each division on track to meet its organic gross profit growth targets for 2025.
The company also expects declining interest rates to positively impact this year’s EPS performance.
The healthcare services provider reaffirmed its mid-term guidance, stating it remains confident in delivering at least 80% of its €200 million EBITDA target for 2028 through organic growth.
The company also mentioned it maintains "an active pipeline of acquisition opportunities" as M&A continues to be an important part of its growth strategy.
Full interim results will be published on September 2, which is expected to include divisional EBITDA disclosure for the first time.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.